C vs TRDA · P/E 16, rev $85.22B vs P/E 12, rev $210.8M
Citigroup Inc. (C) versus Entrada Therapeutics Inc (TRDA) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
C currently screens at market cap $214.73B and trailing P/E 15.5. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
Not investment advice. Open the C and TRDA stock pages for the full models.
Not investment advice.